SHANGHAI, Feb. 13, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2014 after the New York Stock Exchange closes on Thursday, March 5, 2015 (which will be Friday morning, March 6, 2015 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Friday, March 6, 2015, to discuss the fourth-quarter 2014 financial results and recent business activities. The conference call may be accessed by calling:
Mainland China 4001 200 539
Hong Kong 800 905 927
Singapore 800 616 3222
United Kingdom 0800 015 9725
United States 1855 298 3404
United States—New York (toll) +1 631 5142 526
Other countries (toll) +65 6823 2299
Conference ID 2198866
A telephone replay will be available two hours after the call's completion at:
Mainland China 4001 842 240
Hong Kong 800 966 697
Singapore 800 616 2127
United Kingdom 0800 169 7301
United States 1866 846 0868
Conference ID 2198866
A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For further information, please visit http://www.wuxiapptec.com.
For more information, please contact:
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.